-1.83%
Today
Loading 1D prices…
Company profile
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, its precision oncology portfolio consists of n RUO-targeted methylation-based platform that enables applications for disease prognostication, risk stratification, minimal residual disease detection, and recurrence and relapse monitoring. The company was incorporated in 2015 and is headquartered in Menlo Park, California.
Sector
Health Care
Industry
Services-Medical Laboratories
Exchange
Nasdaq
Display currency
USD
Location
Menlo Park, CA, United States
Employees
910
Fiscal year end
1231
CIK
1699031
Session & valuation
Latest annual period
Deterministic peer set
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| VCYTVeracyte Inc. Common Stock | $3.3B | $517.1M | +12.84% | $0.82 | -2.81% | Buy |
| CELCCelcuity Inc. Common Stock | $4.1B | $0.00 | — | -$3.79 | -2.39% | Buy |
| CDNACareDx Inc. Common Stock | $2.6B | $379.8M | -5.62% | -$0.40 | +0.48% | Buy |
| BLLNBillionToOne Inc. Class A Common Stock | $4.7B | $305.1M | +2.44% | $0.14 | +0.26% | Buy |
| RDNTRadNet Inc. Common Stock | $5.9B | $2B | -0.91% | -$0.25 | +1.60% | Buy |